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Abstract
Telomerase activity is present in most human malig-
nant tumors, whereas it is generally not detectable,
with some exceptions, in normal cells. Therefore, it
represents a potential tool for tumor detection. In the
present study, telomerase activity was determined in
urine from 79 healthy individuals and 121 previously
untreated bladder cancer patients using a highly sen-
sitive telomeric repeat amplification protocol (TRAP)
assay and the results were expressed as arbitrary
enzymatic units (AEU). This approach enabled us to
identify cutoff values characterized by high sensitivity
(from 75% to 93%) and specificity (from 72% to 92%).
Moreover, analysis as a function of gender showed a
higher accuracy of TRAP assay in males (93%
sensitivity and 90% specificity at the cutoff of 50
AEU) than in females. This sensitivity was confirmed in
patients with nonassessable or negative cytology. In
women, morphological and immunocytochemical de-
terminations using a human telomerase reverse trans-
criptase monoclonal antibody (anti-hTERT) recently
developed in our laboratory showed a large fraction of
immunoreactive inflammatory or nonbladder cells,
which may justify the false-positive TRAP results. In
conclusion, this assay represents an important non-
invasive diagnostic tool to detect bladder cancer also
in patients with negative or nonassessable urine
cytology and with low-grade and early-stage lesions.
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Introduction
Carcinoma of the urinary bladder is the most common
malignant tumor of the urinary tract and the second most
common malignancy, after prostatic carcinoma, of the
urogenital system, affecting about 15 in 100,000 of the
general population. Males are about three times more
frequently affected than females [1].
The importance of a noninvasive technique for the
diagnosis of patients with carcinoma of the urinary bladder
was recognized more than 50 years ago. However, cystos-
copy is still the ‘‘gold standard’’ because available noninvasive
methods have neither sufficient sensitivity nor specificity to
compete for routine use [1].
Themost commonly utilized cytological examination of urine
has a high specificity, but gives false-negatives in about half
of cases, mainly in patients with low-grade, early-stage
tumors [2]. It is therefore evident that more specific and
sensitive noninvasive diagnostic approaches are warranted,
and recent evidence has suggested that telomerase activity in
urine is a potentially useful marker for the early detection of
bladder cancer [3–8].
Telomerase activity is present in most human malignant
tumors, whereas it is generally not detectable in normal so-
matic cells [9,10], with the exception of inflammatory elements,
germline and hematopoietic stem cells [11,12], cells of the
epidermal basal layer [13], and intestinal crypt cells [14,15].
Telomerase consists of three subunits: an RNA component
(hTR), which acts as a template for DNA replication [16]; a
telomerase-associated protein (TP1) [17] of unknown function;
and the telomerase reverse transcriptase (hTERT), which is
responsible for catalytic activity [12,18]. Telomerase activity is
generally determined by the telomeric repeat amplification
protocol (TRAP) assay, a polymerase chain reaction (PCR)–
based method that has been available for about a decade [9].
This determination is a potentially useful approach to detect
tumors of the urinary tract in screening programs as it requires a
small amount of urine, is noninvasive, and is inexpensive [19].
In the present study, we attempted to improve the sensi-
tivity and specificity of the TRAP assay by using an internal
standard developed by Wright et al. [20] and by adding a
reference curve to quantitate the results of TRAP assay. We
also aimed to find an explanation for the false diagnostic
results by utilizing a new monoclonal antibody (anti-hTERT)
developed in our laboratory.
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Materials and Methods
Urine and Tumor Biological Material
The study was performed on an overall series of 200
individuals. Urine samples were collected from 79 healthy
individuals recruited among laboratory personnel and 121
patients at first diagnosis of histologically confirmed bladder
cancer, recruited in the Departments of Urology of Pierantoni
Hospital (Forlı`, Italy) and Infermi Hospital (Rimini, Italy).
Patients had not previously received locoregional or system-
ic treatment. Overall, there were 140 males (41 healthy
individuals, 99 patients) and 60 females (38 healthy individ-
uals, 22 patients).
According to World Health Organization (WHO) score
classification, 13 patients had grade I, 50 had grade II, and
53 had grade III tumors. Two carcinomas were in situ.
Grading information was not evaluable in only three
patients.
Aliquots of each urine sample were used for cytological
diagnosis, immunocytochemical determination, and TRAP
assay to detect telomerase activity. Samples were stored at
70jC for a maximum of 2 months [21].
Telomerase Assay
Cell extract preparation and TRAP assay were carried out
as previously described [9,20], with some modifications [21].
Briefly, urine samples were centrifuged at 850g for 10
minutes at 4jC, washed once in phosphate-buffered saline
(PBS), and centrifuged at 2300g for 5 minutes at 4jC.
Samples were then resuspended in 200 ml of ice-cold TRAP
lysis buffer [21], incubated on ice for 30 minutes, and
centrifuged at 10,000g for 20 minutes at 4jC. The super-
natants were removed and stored at 70jC. Protein con-
centrations of cell extracts were measured using the Bio-Rad
protein assay (Bio-Rad Laboratories, Hercules, CA) and
aliquots containing 1 mg of protein were used for the telomer-
ase assay.
Telomerase products were evaluated on fluorescence
electropherograms and the total area underlying the differ-
ent peaks was calculated (Figure 1). To obtain semiquan-
titative levels of telomerase activity, an internal telomerase
assay standard (ITAS; 25 ag [20]) amplified by the same
two primers used for the telomerase activity assay was
included in the TRAP buffer. Protein concentrations
corresponding to 10, 30, 100, 300, 1000, and 3000 cells
of a human bladder cancer line (MCR) [21] were analyzed
in each assay. Telomerase activity in MCR cells was
expressed relative to the activity of 100-cell equivalents
and normalized to the internal standard. To obtain quanti-
tative evaluations, the areas of each sample were also
normalized to the ITAS peak. The relative telomerase
activity was correlated to the corresponding MCR cell
number and expressed in arbitrary enzymatic units
(AEU). All experiments were performed in duplicate and,
when variations were greater than 15%, as observed in
about 10% of cases, a third analysis was performed.
Telomerase activity was expressed as a continuous vari-
able in all the analyses.
hTERT Immunocytochemistry
Immunocytochemical evaluation of hTERT was carried
out on urine samples from 63 healthy individuals (35 males,
28 females) and 12 patients (eight males, four females)
recruited toward the end of the study once the monoclonal
antibody was available.
Urine was filtered with a 5-mm round paper filter (Millipore
Corporation, Bedford, MA). The filter was then placed on a
glass slide and stored for 10 minutes at 20jC to permit cell
transfer. The samples were fixed in acetone for 10 minutes
followed by chloroform for 5 minutes and rinsed in 100%
alcohol for 2 minutes, 90% for 1 minute, and 70% for 1
minute and then washed in distilled water.
Endogenous peroxidase was quenched in 3% hydrogen
peroxidase for 10 minutes. After a 5-minute wash in PBS,
aspecific sites were blocked with 1% bovine serum albumin
in PBS for 20 minutes.
Telomerase was determined using a monoclonal anti-
body (tel 3 36-10; DIESSE Diagnostica Senese, Siena,
Italy), obtained by immunizing female Lewis rats with a
fragment of cDNA directed against the hTERT polypeptide
sequences of the telomerase enzyme. The antibody was
used at a final concentration of 40 mg/ml using a diluent
with background-reducing components (Dako Corporation,
Carpinteria, CA) and placed in contact with cells for 1 hour
at room temperature.
The samples were washed twice in PBS–Tween (0.05%)
and incubated for 30 minutes with biotinylated anti– rat
secondary antibody (Dako Corporation) diluted 1:300. Sam-
ples were then washed twice in PBS–Tween (0.05%) and
incubated in streptavidin–peroxidase conjugate (LSAB + kit;
Dako Corporation) for 15 minutes. Samples were processed
with diaminobenzidine/hydrogen peroxidase chromogen
solution (DAB + liquid substrate–chromogen solution; Dako
Corporation) for 5 minutes. Hematoxylin was used to coun-
terstain cell nuclei.
Figure 1. Lane 1 represents the electropherogram of a urine control with only
one peak corresponding to ITAS. Lanes 2 to 5 represent samples from
bladder cancer patients.
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Primary antibody was omitted to obtain an intra-assay
control. Paraffin-embedded MCF-7 human breast cancer
cells were used as positive controls, and differentiated
nervous and muscular tissues served as negative controls.
Immunostaining was observed in the nuclei of the MCF-7 cell
line and in both the nucleus and cytoplasm of exfoliated
epithelial cells in urine samples.
Statistical Analysis
The most accurate cutoff values to discriminate between
healthy individuals and patients were calculated on the
overall series and also separately for the male and female
subgroups using the receiver operating characteristic (ROC)
curve [22]. In the ROC curve, true-positive rates (sensitivity)
were plotted against false-positive rates (1  specificity) for
all classification points.
Sensitivity, specificity, and relative 95% confidence inter-
val (95% CI) were calculated for the most discriminant
cutoff values.
Results
Urine telomerase activity ranged from 0 to 117 AEU in
healthy individuals and from 0 to 262 AEU in patients, with
median values of 10 and 82, respectively. Specifically,
values lower than 20 AEU were observed in 67% of healthy
individuals compared to only 6% of patients, and values
higher than 80 AEU were detected in 56% of patients and
only very occasionally in healthy individuals.
In patients, urine enzyme activity was not related to age or
gender, and similar median values (82, 84, and 82 AEU)
were observed for grade I, grade II, and grade III tumors,
respectively.
The diagnostic accuracy of telomerase activity was eval-
uated for the overall series using ROC curve analysis
(Figure 2). The sensitivity and specificity for the most rele-
vant telomerase levels are reported in Table 1. For these
cutoff values, specificity ranged from 72% to 92% and
sensitivity ranged from 93% to 75%. Of the 121 patients,
61 (50%) had nonassessable or negative cytology. For this
subgroup, sensitivity was similar to that observed for the
overall series, showing the ability of TRAP assay to detect
the presence of tumors when cytology provides either false-
negative or no information at all (Table 1).
A breakdown analysis as a function of gender showed a
generally higher diagnostic power of telomerase activity in
males than in females, with a different accuracy in terms of
both sensitivity and specificity for each AEU value (Figure 3).
In males, specificity ranged from 85% to 98% and sensitivity
ranged from 94% to 77%. In particular, 93% sensitivity and
90% specificity were observed using 50 AEU as cutoff, and
this sensitivity was confirmed in patients with nonassessable
or negative cytology (Table 2). Somewhat less satisfactory
results were obtained for women, for whom we did not find a
single cutoff value capable of providing acceptable sensitivity
and specificity (Figure 3 and Table 3). No breakdown anal-
ysis was performed for patients with nonassessable or
negative cytology due to the low number of women recruited.
Figure 2. ROC curve of telomerase activity for the overall series (200 cases). Figure 3. ROC curve of telomerase activity for males and females.
Table 1. Sensitivity and Specificity of Urine Telomerase Activity for the Overall Series.
Cut-off (AEU) All Individuals (200 Cases) Individuals with Nonassessable or
Negative Cytology (61 Cases)
Specificity (%) 95% CI Sensitivity (%) 95% CI Sensitivity (%) 95% CI
35 72 61–81 93 87–97 92 82–96
40 76 65–84 93 87–97 92 82–96
45 79 68–86 93 87–97 92 82–96
50 81 71–89 92 85–95 90 80–95
55 83 77–87 88 82–94 85 76–94
60 89 84–93 83 76–90 80 70–90
65 92 87–95 75 67–83 72 66–88
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In an attempt to improve TRAP assay specificity in
women, we investigated possible reasons for the false-
positive results using a monoclonal antibody raised against
hTERT (Figure 4A). Morphological and immunocytochemical
analyses showed, as expected, the presence of a high
number of inflammatory and nonbladder epithelial cells,
accounting for up to 80% of the whole cell population, which
were mainly positive to hTERT monoclonal antibody
(Figure 4B). This observation might justify the high number
of false-positives in females. With regard to the very few
TRAP assay false-negative urine samples, morphological
examination showed a maximum presence of normal epi-
thelial cells, a moderate to very low presence of inflammatory
components, and a total absence of tumor cells. Therefore,
the limits of TRAP assay sensitivity could be attributed to the
nonrepresentativity of the urine samples, which can be
evidenced a priori by morphological examination.
Discussion
The identification of new molecular markers is one of the
most challenging goals for the early noninvasive detection of
bladder cancer. Although cystoscopy is considered the ‘‘gold
standard’’ for the diagnosis of bladder malignancies, it is a
costly, uncomfortable, and invasive procedure for patients.
Urine cytology is a simple and specific procedure, but it has
relatively low sensitivity, especially for the detection of low-
grade lesions [23]. Telomerase has recently been proposed
as a reliable marker of bladder malignancies because it is
present in almost all bladder cancers.
Comparative analyses of various screening methods for
the diagnosis of bladder cancer have shown that telomerase
has the highest combination of sensitivity and specificity with
respect to urine cytology and other biochemical marker
determinations [4,6,7,24–29].
Telomerase activity evaluation has undergone an im-
provement in its methodology. The most important advance
has been the development of the TRAP assay, which is
capable of detecting enzyme activity in as few as 10 immortal
cancer cells [20]. However, telomerase activity is also pres-
ent in some types of normal cells, especially proliferative
stem cells and activated lymphocytes [10,11], and this can
interfere with the interpretation of TRAP results. Moreover,
this approach is a complex procedure as it requires a PCR
amplification step and is susceptible to possible inhibitors of
the PCR reaction.
TRAP assay, as initially used, provided only qualitative
information (i.e., positive versus negative samples). The
assay was subsequently modified with the aim of furnishing
quantitative results and of improving sensitivity [30–33]. In
fact, a quantitative analysis of telomerase activity is neces-
sary to distinguish the upregulation of telomerase in cancer
cells [34].
We recently modified the TRAP assay protocol, which
includes ITAS [20], by adding a reference curve to quan-
titate the results and ensure intersample comparability [21].
In this way, telomerase activity can be expressed and
analyzed as a continuous variable. In the present study,
we demonstrated on an adequate case series that quan-
titative determination and appropriate statistical analysis
Table 2. Sensitivity and Specificity of Urine Telomerase Activity for Males.
Cut-off (AEU) All Individuals (140 Cases) Individuals with Nonassessable or
Negative Cytology (48 Cases)
Specificity (%) 95% CI Sensitivity (%) 95% CI Sensitivity (%) 95% CI
35 85 71–93 94 87–97 94 83–98
40 88 74–95 94 87–97 94 83–98
45 88 74–95 94 87–97 94 83–98
50 90 77–96 93 86–97 94 83–98
55 93 80–97 88 80–93 88 75–94
60 93 80–97 85 77–91 85 73–93
65 98 87–100 77 68–84 79 66–88
Figure 4. Immunoreactivity to monoclonal antibody anti-hTERT. (A) Bladder tumor cells. (B) Inflammatory and normal epithelial cells.
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are able to identify cutoff values characterized by high
sensitivity and specificity.
More importantly, the same predictive accuracy of the
TRAP assay was observed for the detection of low-grade
tumors and for the subgroup of cases with nonassessable or
negative cytology, who represent 50% of the population and
for whom determination of telomerase activity may be the
only noninvasive diagnostic tool.
Furthermore, analyzing, for the first time to our knowl-
edge, the diagnostic accuracy of urine telomerase as a
function of gender, we identified a cutoff value characterized
by 93% sensitivity and 90% specificity in males, who repre-
sent the subgroup with, by far, the highest incidence of
cancer. The use of the anti-hTERT antibody developed in
our laboratory (permitting a microscopic visualization of
different cell components) showed a higher fraction of im-
munoreactive inflammatory and nonbladder epithelial cells in
women than in men. This is probably due to the shorter
female urethra, which favors the entrance of bacteria into the
bladder and which could, at least in part, explain the false-
positive TRAP assay results. Therefore, once the immuno-
reactivity of contaminating elements largely present in urine
samples has been demonstrated, it will also be possible to
improve diagnostic accuracy in women by subtracting the
telomerase activity belonging to nontumor epithelial cells
from the total TRAP values.
Our results show that urine telomerase activity deter-
mined by a quantitative TRAP assay and used as the only
approach or sequentially in individuals with negative or non-
assessable urine cytology represents an important noninva-
sive diagnostic tool for the detection of bladder cancer,
including low-grade and low-stage lesions.
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